Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/61219
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels |
Autor: | Bolós, M.; Fernández, Silvia Venero; Torres Alemán, Ignacio CSIC ORCID | Fecha de publicación: | 2010 | Editor: | American Society for Biochemistry and Molecular Biology | Citación: | Journal of Biological Chemistry 285: 17693- 17700 (2010) | Resumen: | Reduced brain input of serum insulin-like growth factor I (IGF-I), a potent neurotrophic peptide, may be associated with neurodegenerative processes. Thus, analysis of the mechanisms involved in passage of blood-borne IGF-I into the brain may shed light onto pathological mechanisms in neurodegeneration and provide new drug targets. A site of entrance of serum IGF-I into the brain is the choroid plexus. The transport mechanism for IGF-I in this specialized epithelium involves the IGF-I receptor and the membrane multicargo transporter megalin/LRP2. We have now analyzed this process in greater detail and found that the IGF-I receptor interacts with the transmembrane region of megalin, whereas the perimembrane domain of megalin is required for IGF-I internalization. Furthermore, a GSK3 site within the Src homology 3 domain of the C-terminal region of megalin is a key regulator of IGF-I transport. Thus, inhibition of GSK3 markedly increased internalization of IGF-I, whereas mutation of this GSK3 site abrogated this increase. Notably, oral administration of a GSK3 inhibitor to adult wild-type mice or to amyloid precursor protein/presenilin 1 mice modeling Alzheimer amyloidosis significantly increased brain IGF-I content. These results indicate that pharmacological modulation of IGF-I transport by megalin may be used to increase brain availability of serum IGF-I. Interestingly, GSK3 inhibitors such as those under development to treat Alzheimer disease may show therapeutic efficacy in part by increasing brain IGF-I levels, an effect already reported for other neuroprotective compounds. © 2010 by The American Society for Biochemistry and Molecular Biology, Inc. | URI: | http://hdl.handle.net/10261/61219 | DOI: | 10.1074/jbc.M109.096594 | Identificadores: | doi: 10.1074/jbc.M109.096594 issn: 0021-9258 |
Aparece en las colecciones: | (IC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
20
checked on 23-abr-2024
SCOPUSTM
Citations
33
checked on 17-abr-2024
WEB OF SCIENCETM
Citations
30
checked on 24-feb-2024
Page view(s)
334
checked on 24-abr-2024
Download(s)
107
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.